Strategic Partnerships Position Stratatech as a preferred collaborator for government, academic, and military-affiliated biomanufacturing projects, leveraging recent partnerships with AFIP, UW–Madison, UW–Milwaukee, and Waisman to target research institutes and defense-related healthcare initiatives.

Regenerative Medicine Focus Target opportunities in wound healing and scar reduction by emphasizing Stratatech's cell-based therapeutic platforms and leadership in regenerative medicine to attract biopharma collaborators seeking advanced skin regeneration solutions.

Scale and Capabilities Leverage the small-to-mid enterprise profile (51–200 employees) and notable funding to pursue contract research, early-stage development, and GMP-like partnerships with larger biopharma players seeking agile innovation partners.

Funding Readiness Highlight available funding and revenue range to prospective clients, pitching cost-effective collaborations and milestone-based engagements that align with Stratatech’s $29M funding and $10–$25M revenue band.

Technology Synergies Explore joint development or deployment of bioengineering and regenerative medicine solutions using existing tech stack and data capabilities, offering analytics-backed clinical and translational studies to prospective clients.